Literature DB >> 24370751

Influences of nasal lavage collection-, processing- and storage methods on inflammatory markers--evaluation of a method for non-invasive sampling of epithelial lining fluid in cystic fibrosis and other respiratory diseases.

Julia Hentschel1, Ulrike Müller2, Franziska Doht2, Nele Fischer2, Klas Böer3, Jürgen Sonnemann4, Christina Hipler5, Kerstin Hünniger6, Oliver Kurzai6, Udo R Markert7, Jochen G Mainz2.   

Abstract

BACKGROUND: Non-invasive sampling of airway epithelial-lining-fluid by nasal lavage (NL) is an emerging method to monitor allergy, infection and inflammation in patients with respiratory diseases. However, the influences of collection-, processing- and storage-methods have not been sufficiently evaluated and standardized.
METHODS: Influences of repeated NL, centrifugation setups, repeated freezing and thawing, and protease inhibitors on mediator concentration were evaluated in healthy controls and CF patients, which serve as a model for chronic bacterial infection and inflammation. Polymorphonuclear leukocyte elastase (NE)/myeloperoxidase (MPO)/interleukin (IL)-1/IL-6/IL-8 and tumour necrosis factor alpha (TNF) concentrations were measured using ELISA and Multiplex Bead-Arrays.
RESULTS: NL-repetition within 0.5-4h markedly decreased NE, IL-8 and MPO-concentrations for up to 70%. NL centrifugation up to 250×g for cellular differentiation did not significantly influence mediator concentration in native and processed NL fluid. NL freezing and thawing markedly decreased IL-8 and MPO concentrations by up to 50% while NE remained stable. In contrast to preceding reports, storing at -70°C for ≥5 years led to significantly reduced mediator concentrations in NL compared to contemporary analyses, being most pronounced for IL-1β, IL-6 and TNFa. Storing of samples in the presence of protease inhibitors led to an increase in marker concentration for IL-8 (+27%) and MPO (+15%) even after one year of storage.
CONCLUSIONS: NL is an easy and robust technique for inflammation monitoring of the upper airways. For the first time we have shown that diagnostic NL should be performed only once daily to get comparable results. Whereas NL-fluid can be stored unprocessed at -70°C for cytokine analysis over 1-2 years with protease inhibitors supporting stability, ≥5 years storage as well as repeated freezing and thawing should be avoided.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Centrifugation; Cystic fibrosis; Cytokines; Cytology; Nasal lavage; Sampling technique

Mesh:

Substances:

Year:  2013        PMID: 24370751     DOI: 10.1016/j.jim.2013.12.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  16 in total

Review 1.  Noninvasive effects measurements for air pollution human studies: methods, analysis, and implications.

Authors:  Jaime Mirowsky; Terry Gordon
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-01-21       Impact factor: 5.563

2.  Cytokine signature clusters as a tool to compare changes associated with tobacco product use in upper and lower airway samples.

Authors:  Alexis D Payton; Alexia N Perryman; Jessica R Hoffman; Vennela Avula; Heather Wells; Carole Robinette; Neil E Alexis; Ilona Jaspers; Julia E Rager; Meghan E Rebuli
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-03-23       Impact factor: 5.464

3.  Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.

Authors:  Wibke Katharina Janhsen; Christin Arnold; Julia Hentschel; Thomas Lehmann; Wolfgang Pfister; Michael Baier; Klas Böer; Kerstin Hünniger; Oliver Kurzai; Uta-Christina Hipler; Jochen Georg Mainz
Journal:  Med Microbiol Immunol       Date:  2016-07-04       Impact factor: 3.402

4.  Novel applications for a noninvasive sampling method of the nasal mucosa.

Authors:  Meghan E Rebuli; Adam M Speen; Phillip W Clapp; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-12-23       Impact factor: 6.011

5.  Pseudomonas aeruginosa Acquisition in Cystic Fibrosis Patients in Context of Otorhinolaryngological Surgery or Dentist Attendance: Case Series and Discussion of Preventive Concepts.

Authors:  Jochen G Mainz; Andrea Gerber; Michael Lorenz; Ruth Michl; Julia Hentschel; Anika Nader; James F Beck; Mathias W Pletz; Andreas H Mueller
Journal:  Case Rep Infect Dis       Date:  2015-03-18

6.  Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.

Authors:  Ulrike Müller; Julia Hentschel; Wibke K Janhsen; Kerstin Hünniger; Uta-Christina Hipler; Jürgen Sonnemann; Wolfgang Pfister; Klas Böer; Thomas Lehmann; Jochen G Mainz
Journal:  Mediators Inflamm       Date:  2015-06-21       Impact factor: 4.711

7.  Nasal saline as a placebo in a rhinosinusitis study.

Authors:  Ahmet Karadag; Ferhat Catal
Journal:  Drug Des Devel Ther       Date:  2014-08-20       Impact factor: 4.162

8.  Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness.

Authors:  Jaideep Dhariwal; Jeremy Kitson; Reema E Jones; Grant Nicholson; Tanushree Tunstall; Ross P Walton; Grace Francombe; Jane Gilbert; Andrew J Tan; Robert Murdoch; Onn Min Kon; Peter J Openshaw; Trevor T Hansel
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Dynamics of soluble and cellular inflammatory markers in nasal lavage obtained from cystic fibrosis patients during intravenous antibiotic treatment.

Authors:  Julia Hentschel; Manuela Jäger; Natalie Beiersdorf; Nele Fischer; Franziska Doht; Ruth K Michl; Thomas Lehmann; Udo R Markert; Klas Böer; Peter M Keller; Mathias W Pletz; Jochen G Mainz
Journal:  BMC Pulm Med       Date:  2014-05-13       Impact factor: 3.317

10.  Inflammatory Mediator Profiling of n-butanol Exposed Upper Airways in Individuals with Multiple Chemical Sensitivity.

Authors:  Thomas Meinertz Dantoft; Sine Skovbjerg; Linus Andersson; Anna-Sara Claeson; Nina Lind; Steven Nordin; Susanne Brix
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.